FOCUS DIAGNOSTICS Trademark
FOCUS DIAGNOSTICS is a USPTO trademark filed by DIASORIN MOLECULAR LLC. Status: Registered.
Trademark Facts
| Mark | FOCUS DIAGNOSTICS |
|---|---|
| Serial Number | 78458042 |
| Registration Number | 3415579 |
| Status | Registered |
| Filing Date | 2004-07-28 |
| Registration Date | 2008-04-22 |
| Mark Type | Combined |
| Nice Classes | 001 (Chemicals), 005 (Pharmaceuticals), 010 (Medical Devices), 042 (Software & IT) |
| Owner | DIASORIN MOLECULAR LLC |
| Attorney of Record | Jose Jimenez |
| Prosecution Events | 52 |
| Latest Event | RNL1 on 2018-11-26 |
Goods & Services
Class 001: Diagnostic reagents and assay components for scientific and research testing; diagnostic kits comprised of diagnostic reagents and assay components for scientific and research testing; diagnostic testing apparatus for scientific and research testing; Class 005: Diagnostic reagents and assays for clinical and medical laboratory use; diagnostic kits consisting of diagnostic reagents and assays for clinical and medical laboratory use; Class 010: diagnostic testing apparatus for disease indicators in human blood, urine, sputum and tissue for clinical and medical laboratory use; diagnostic testing apparatus for disease indicators in human blood, urine, sputum and tissue for scientific and research testing; Class 042: [ Medical laboratory services, namely, microbiological, molecular, genetic, immunological, histopathological, hematological, biochemical and chemical testing; testing of human, animal and environmental specimens and isolates of microorganisms; scientific, research and medical clinical testing of human, animal and environmental specimens and isolates of microorganisms; scientific, research and medical clinical testing and consulting services in the fields of pharmaceuticals, biotechnology and healthcare; data warehousing and analysis of laboratory test results; medical services, namely, monitoring services, diagnostic services, and imaging services for all phases of clinical trials; and epidemiological studies for late phase clinical trials and post-marketing surveillance ]